Investors seeking defensive equity exposure often turn to healthcare because essential medical products and services do not typically get deferred during market downturns. Two broadly traded iShares ETFs - IXJ and IYH - are widely used for this purpose, each emphasizing different elements of defense.
Performance and fund metrics
Key fund metrics provide a snapshot of how these ETFs compare. According to the figures used in this analysis, IXJ has $4.35 billion in assets under management, an expense ratio of 0.46%, a 1-year return of +20.1%, a 3-year return of +23.6%, a year-to-date return of +3.4% and a dividend yield of 1.69%. IYH lists $3.56 billion AUM, a 0.43% expense ratio, +24.0% over one year, +27.4% over three years, a YTD return of +5.4% and a 0.96% dividend yield. IHF, the healthcare providers fund, shows $1.25 billion AUM, a 0.43% expense ratio, a 1-year return of +37.0%, a 3-year return of +11.7% and a YTD return of +18.3% with a 0.35% dividend yield.
All three ETFs were trading higher intraday on Aug 5, 2026, with IXJ and IYH each up about +1.3-1.4% that day, highlighting healthcare's relative resilience in the market.
IXJ - Global defensive positioning
IXJ is positioned as the more globally diversified defensive choice. Its geographic weightings are shown as 72.8% North America, 22.2% Europe Developed and 4% Asia. This spread reduces reliance on any single country's policy environment. IXJ's largest holdings reflect a tilt toward mega-cap pharmaceutical and medtech names, with Eli Lilly (LLY) at 10.3%, Johnson & Johnson (JNJ) at 7.0% and AbbVie (ABBV) at 5.0%. Large non-U.S. pharmaceuticals such as Novartis (NOVN) at 3.7% and Roche (ROPC) at 3.9% are also significant portfolio anchors. The fund's 1.69% dividend yield provides an income buffer that can be attractive when equity returns narrow.
IYH - Concentrated U.S. exposure with higher recent returns
IYH is concentrated in U.S.-listed healthcare names, increasing exposure to U.S. regulatory developments. Eli Lilly is a substantial single holding at 15.1% and Johnson & Johnson accounts for 10.2% of the fund. Over three years, IYH's reported return of +27.4% outpaced IXJ's +23.6%, suggesting a stronger recent performance profile, albeit with greater single-country concentration. For investors prioritizing domestic exposure and willing to accept U.S. policy risk, IYH can be the more performance-oriented defensive play.
IHF - Providers fund classified as less defensive
IHF, focused on healthcare providers and managed care, recorded a 1-year gain of +37.0%. That rapid appreciation is notable, but the fund's underlying exposure to managed care introduces earnings volatility linked to medical loss ratios. The article frames IHF's recent run as more characteristic of offensive performance rather than pure defense.
Intraday security moves cited
Intraday moves cited alongside the funds include LLY +3.18%, NOVN +0.5%, ROPC +1.68%, JNJ +0.85%, IXJ +1.00%, ABBV +1.81%, IYH +0.99% and IHF -0.49%.
Conclusion
For investors prioritizing the purest defensive attributes, IXJ is presented as the preferred choice because geographic diversification reduces single-country policy risk, the dividend yield acts as a cushion and a mega-cap quality tilt supports cash-flow resilience. IYH offers a higher recent return profile through concentrated U.S. exposure and may suit investors comfortable with U.S.-centric regulatory risk. IHF's strong short-term performance is noted but is characterized as less defensive due to managed care earnings sensitivity.